HLS Therapeutics Inc Stock Toronto S.E.
Equities
AM
CA05328X1015
Pharmaceuticals
Sales 2024 * | 56.7M 77.49M | Sales 2025 * | 62.27M 85.1M | Capitalization | 80.12M 110M |
---|---|---|---|---|---|
Net income 2024 * | -23M -31.43M | Net income 2025 * | -21M -28.7M | EV / Sales 2024 * | 1.41 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.29 x |
P/E ratio 2024 * |
-4.18
x | P/E ratio 2025 * |
-5.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on HLS Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 23-04-30 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Ryan Lennox
CMP | Compliance Officer | 43 | 18-05-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 21-06-17 |
Laura Brege
BRD | Director/Board Member | 66 | 19-03-20 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
1st Jan change | Capi. | |
---|---|---|
+26.13% | 75.74B | |
-5.35% | 23.24B | |
+15.24% | 8.76B | |
-6.70% | 7.68B | |
-33.02% | 6.69B | |
+20.45% | 5.58B | |
+3.37% | 4.22B | |
-3.66% | 3.99B | |
+14.24% | 3.39B |